PLATELET GROWTH FACTOR (TPO): THE NEXT EPO? GENENTECH, ZYMOGENETICS
PLATELET GROWTH FACTOR (TPO): THE NEXT EPO? GENENTECH, ZYMOGENETICS have separately isolated and cloned a protein that stimulates the growth of platelets. The companies' early research on the compound, believed to be thrombopoietin, is reported in the June 16 issue of Nature. Novo Nordisk subsidiary ZymoGenetics, in collaboration with University of Washington researchers, reported that in mice, platelet levels (but not hematocrit or white blood cell levels) were elevated fourfold on the fifth day following treatment with the company's purified protein.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth